+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Chronic Obstructive Pulmonary Disease Therapeutics Market by Product, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010864
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market is evolving rapidly amid increasing disease prevalence, rising patient expectations, and advances in respiratory medicine. Senior decision-makers face a dynamic landscape shaped by novel therapies, technological integration, and shifting regulatory policies.

Market Snapshot: COPD Therapeutics Market Growth

The COPD therapeutics market grew from USD 21.78 billion in 2024 to USD 23.41 billion in 2025. It is forecast to achieve a CAGR of 7.41%, reaching USD 33.46 billion by 2030. Growth is driven by technological advancements in inhaled delivery, increasing adoption of combination therapies, and expanding access in emerging healthcare systems. Market competition is intensifying as established pharmaceutical leaders and biotech innovators accelerate R&D pipelines and adapt to evolving supply chain scenarios, including tariff-related factors. This growth reflects an ecosystem where regulatory approvals, healthcare infrastructure, and patient-centric models collaboratively shape therapeutic demand and innovation.

Scope & Segmentation of the COPD Therapeutics Market

This research report delivers strategic insights and detailed segmentation on the COPD therapeutics market ecosystem:

  • Product Types: Antibiotics, bronchodilators (long acting beta agonists, long acting muscarinic antagonists, short acting beta agonists, short acting muscarinic antagonists), combination products (inhaled corticosteroid and long acting beta agonist, long acting muscarinic antagonist and long acting beta agonist, short acting muscarinic antagonist and short acting beta agonist), corticosteroids, mucolytics.
  • Route of Administration: Inhalation (dry powder inhaler, metered dose inhaler, nebulizer), injectable, oral.
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy.
  • End Users: Clinics, homecare, hospitals.
  • Regions Covered: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Leading Companies: GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, AstraZeneca plc, Novartis AG, Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici S.p.A, Cipla Limited, Sun Pharmaceutical Industries Ltd, Sandoz International GmbH, Mylan N.V.

Key Takeaways for Senior Executives

  • Therapeutic approaches are shifting from traditional bronchodilators to more integrated regimens, incorporating fixed-dose combinations and advanced biologics to address disease heterogeneity.
  • Enhanced inhalation devices and digital health platforms are driving improvements in patient adherence, facilitating telehealth services, and creating opportunities for real-time data collection and analysis.
  • Multidisciplinary collaboration across pharmaceutical, device, and tech sectors is increasing, promoting the development of personalized care solutions and enabling faster market adaptation.
  • Regional regulatory frameworks and reimbursement policies significantly influence product adoption, with private insurance in developed markets supporting uptake of premium therapeutics and public initiatives in emerging regions focused on expanding access.
  • Strategic partnerships, acquisitions, and co-development agreements are extending organizational reach, pipeline diversity, and manufacturing capabilities to meet nuanced clinical and market demands.

Tariff Impact: Supply Chain Resilience and Market Response

The 2025 US tariffs have introduced new complexities into the COPD therapeutics supply chain, affecting sourcing strategies, pricing models, and regional manufacturing initiatives. Companies are emphasizing vertical integration and local API development to minimize exposure to policy-driven volatility. Healthcare systems are simultaneously tightening formularies and exploring value-based agreements to contain costs and sustain patient access, while expedited regulatory pathways for locally produced devices hasten time-to-market for tariff-advantaged products.

Methodology & Data Sources

This research is grounded in a rigorous triangulated methodology, integrating primary interviews with pulmonologists, formulary decision-makers, and supply chain executives, alongside analysis of secondary sources such as regulatory filings and industry databases. External experts reviewed all findings to ensure data reliability and relevance within the COPD therapeutics market.

Why This Report Matters

  • Enables informed strategic planning by presenting a comprehensive view of therapeutic, technological, and policy drivers in the COPD therapeutics market.
  • Equips leaders with actionable insights for navigating emerging supply chain risks, new reimbursement environments, and evolving patient care standards.
  • Supports tailored decision-making by unpacking regional differences in regulation, payer dynamics, and market access pathways.

Conclusion

This report delivers a clear analysis of crucial trends, competitive direction, and actionable strategies to guide decision-makers in the COPD therapeutics sector. By focusing on innovation, adaptability, and patient outcomes, organizations can effectively position themselves in this evolving environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Product
8.1. Introduction
8.2. Antibiotics
8.3. Bronchodilators
8.3.1. Long Acting Beta Agonists
8.3.2. Long Acting Muscarinic Antagonists
8.3.3. Short Acting Beta Agonists
8.3.4. Short Acting Muscarinic Antagonists
8.4. Combination Products
8.4.1. Inhaled Corticosteroid and Long Acting Beta Agonist
8.4.2. Long Acting Muscarinic Antagonist and Long Acting Beta Agonist
8.4.3. Short Acting Muscarinic Antagonist and Short Acting Beta Agonist
8.5. Corticosteroids
8.6. Mucolytics
9. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Inhalation
9.2.1. Dry Powder Inhaler
9.2.2. Metered Dose Inhaler
9.2.3. Nebulizer
9.3. Injectable
9.4. Oral
10. Chronic Obstructive Pulmonary Disease Therapeutics Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Chronic Obstructive Pulmonary Disease Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare
11.4. Hospitals
12. Americas Chronic Obstructive Pulmonary Disease Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Chronic Obstructive Pulmonary Disease Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. GlaxoSmithKline plc
15.3.2. Boehringer Ingelheim International GmbH
15.3.3. AstraZeneca plc
15.3.4. Novartis AG
15.3.5. Teva Pharmaceutical Industries Ltd
15.3.6. Chiesi Farmaceutici S.p.A
15.3.7. Cipla Limited
15.3.8. Sun Pharmaceutical Industries Ltd
15.3.9. Sandoz International GmbH
15.3.10. Mylan N.V.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY LONG ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY LONG ACTING MUSCARINIC ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SHORT ACTING BETA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SHORT ACTING MUSCARINIC ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALED CORTICOSTEROID AND LONG ACTING BETA AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY LONG ACTING MUSCARINIC ANTAGONIST AND LONG ACTING BETA AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY SHORT ACTING MUSCARINIC ANTAGONIST AND SHORT ACTING BETA AGONIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 54. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 55. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 56. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 98. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 99. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 101. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 105. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 106. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 108. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 118. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 119. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 120. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 122. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 126. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 153. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 154. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 155. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 157. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. DENMARK CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 168. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 169. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 171. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. QATAR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 174. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 176. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 178. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. FINLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 196. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 197. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 199. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. EGYPT CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 202. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 203. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 204. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 206. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. TURKEY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 216. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 218. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 220. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. NORWAY CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 223. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 224. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 225. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 227. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. POLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 244. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 245. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 246. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 247. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 248. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 249. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 252. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY BRONCHODILATORS, 2018-2030 (USD MILLION)
TABLE 253. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY COMBINATION PRODUCTS, 2018-2030 (USD MILLION)
TABLE 254. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE THERAPEUTICS MAR

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Chronic Obstructive Pulmonary Disease Therapeutics market report include:
  • GlaxoSmithKline plc
  • Boehringer Ingelheim International GmbH
  • AstraZeneca plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Chiesi Farmaceutici S.p.A
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd
  • Sandoz International GmbH
  • Mylan N.V.

Table Information

Report AttributeDetails
No. of Pages196
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 23.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.46 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030 - Product Image

Chronic Obstructive Pulmonary Disease Treatment Market by Product Type, Drug Class, Route of Administration, Distribution Channel, Therapy Type - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Obstructive Pulmonary Disease Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 343 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2025 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Strategic Business Report

  • Report
  • 299 Pages
  • Global
From
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast 2025-2034 - Product Image

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Chronic Obstructive Pulmonary Disease Drug Market

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions. The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.